WO2008143713A3 - Plant-made west nile virus (wnv) vaccines, vectors and plant codon optimized sequences - Google Patents

Plant-made west nile virus (wnv) vaccines, vectors and plant codon optimized sequences Download PDF

Info

Publication number
WO2008143713A3
WO2008143713A3 PCT/US2007/088512 US2007088512W WO2008143713A3 WO 2008143713 A3 WO2008143713 A3 WO 2008143713A3 US 2007088512 W US2007088512 W US 2007088512W WO 2008143713 A3 WO2008143713 A3 WO 2008143713A3
Authority
WO
WIPO (PCT)
Prior art keywords
plant
wnv
vectors
west nile
nile virus
Prior art date
Application number
PCT/US2007/088512
Other languages
French (fr)
Other versions
WO2008143713A2 (en
Inventor
Kelley A Smith
Charles A Mihaliak
Steven Robert Webb
Donald J Merlo
Steven L Evans
Geoffrey J Letchworth
Original Assignee
Dow Agrosciences Llc
Us Agriculture
Kelley A Smith
Charles A Mihaliak
Steven Robert Webb
Donald J Merlo
Steven L Evans
Geoffrey J Letchworth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Agrosciences Llc, Us Agriculture, Kelley A Smith, Charles A Mihaliak, Steven Robert Webb, Donald J Merlo, Steven L Evans, Geoffrey J Letchworth filed Critical Dow Agrosciences Llc
Priority to CA002671934A priority Critical patent/CA2671934A1/en
Priority to JP2009543249A priority patent/JP2010514698A/en
Priority to EP07874382A priority patent/EP2099916A2/en
Priority to AU2007353773A priority patent/AU2007353773A1/en
Priority to BRPI0721141-4A priority patent/BRPI0721141A2/en
Publication of WO2008143713A2 publication Critical patent/WO2008143713A2/en
Publication of WO2008143713A3 publication Critical patent/WO2008143713A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The subject application provides various compositions of matter directed to West Nile virus (WNV) polypeptides and fragments thereof and polynucleotides, vectors and transformed host cells that encode, direct the expression of, or produce WNV polypeptides as set forth herein. Methods of using the polypeptides and polynucleotides for the production of immune responses in individuals or detecting the presence of WNV specific or neutralizing antibodies are also provided herein.
PCT/US2007/088512 2006-12-22 2007-12-21 Plant-made west nile virus (wnv) vaccines, vectors and plant codon optimized sequences WO2008143713A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002671934A CA2671934A1 (en) 2006-12-22 2007-12-21 Plant-made west nile virus (wnv) vaccines, vectors and plant codon optimized sequences
JP2009543249A JP2010514698A (en) 2006-12-22 2007-12-21 West Nile virus (WNV) vaccine produced by plants, vectors and plant codon optimization sequences
EP07874382A EP2099916A2 (en) 2006-12-22 2007-12-21 Plant-made west nile virus (wnv) vaccines, vectors and plant codon optimized sequences
AU2007353773A AU2007353773A1 (en) 2006-12-22 2007-12-21 Plant-made West Nile virus (WNV) vaccines, vectors and plant codon optimized sequences
BRPI0721141-4A BRPI0721141A2 (en) 2006-12-22 2007-12-21 WEST NILE VIRUS (WNV) VACCINES PRODUCED BY PLANT CODON OPTIMIZED PLANTS, VECTORS AND SEQUENCES.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87151806P 2006-12-22 2006-12-22
US60/871,518 2006-12-22

Publications (2)

Publication Number Publication Date
WO2008143713A2 WO2008143713A2 (en) 2008-11-27
WO2008143713A3 true WO2008143713A3 (en) 2009-03-12

Family

ID=40032322

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/088512 WO2008143713A2 (en) 2006-12-22 2007-12-21 Plant-made west nile virus (wnv) vaccines, vectors and plant codon optimized sequences

Country Status (8)

Country Link
US (1) US7888069B2 (en)
EP (1) EP2099916A2 (en)
JP (1) JP2010514698A (en)
AR (1) AR064500A1 (en)
AU (1) AU2007353773A1 (en)
BR (1) BRPI0721141A2 (en)
CA (1) CA2671934A1 (en)
WO (1) WO2008143713A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2663627T3 (en) 2010-10-11 2018-04-16 Jennewein Biotechnologie Gmbh Novel fucosyltransferases and their applications
WO2012095874A1 (en) 2011-01-11 2012-07-19 Enneffe S.R.L. Adjustable anti -theft device
WO2013191997A1 (en) * 2012-06-18 2013-12-27 Dow Agrosciences Llc Expression of maize codon optimized proteins in pseudomonas fluorescens
GB201704126D0 (en) * 2017-03-15 2017-04-26 Blom Nihlén Kim Andrea Vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112694A2 (en) * 2003-05-23 2004-12-29 Chiron Corporation Immunogenic reagents from west nile virus

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5428147A (en) 1983-04-15 1995-06-27 Mycogen Plant Science, Inc. Octopine T-DNA promoters
US5380831A (en) 1986-04-04 1995-01-10 Mycogen Plant Science, Inc. Synthetic insecticidal crystal protein gene
US5273894A (en) 1986-08-23 1993-12-28 Hoechst Aktiengesellschaft Phosphinothricin-resistance gene, and its use
US5276268A (en) 1986-08-23 1994-01-04 Hoechst Aktiengesellschaft Phosphinothricin-resistance gene, and its use
US5637489A (en) 1986-08-23 1997-06-10 Hoechst Aktiengesellschaft Phosphinothricin-resistance gene, and its use
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
DE3924454A1 (en) 1989-07-24 1991-02-07 Cornelis P Prof Dr Hollenberg THE APPLICATION OF DNA AND DNA TECHNOLOGY FOR THE CONSTRUCTION OF NETWORKS FOR USE IN CHIP CONSTRUCTION AND CHIP PRODUCTION (DNA CHIPS)
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
WO1991009957A1 (en) 1989-12-22 1991-07-11 E.I. Du Pont De Nemours And Company Site-specific recombination of dna in plant cells
US5183740A (en) 1990-02-23 1993-02-02 The United States Of America As Represented By The Secretary Of The Navy Flow immunosensor method and apparatus
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US6027725A (en) 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
JPH07501451A (en) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド Multivalent antigen binding protein
TW261517B (en) 1991-11-29 1995-11-01 Mitsubishi Shozi Kk
WO1993023434A2 (en) 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
AU673859B2 (en) 1992-10-05 1996-11-28 North Carolina State University Method for increasing expression and reducing expression variability of foreign genes in plant cells
AU678787B2 (en) 1992-10-23 1997-06-12 Immunex Corporation Methods of preparing soluble, oligomeric proteins
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
FI92882C (en) 1992-12-29 1995-01-10 Medix Biochemica Ab Oy Disposable test strip and process for its manufacture
US5753439A (en) 1995-05-19 1998-05-19 Trustees Of Boston University Nucleic acid detection methods
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5750352A (en) 1995-08-23 1998-05-12 The Johns Hopkins University Mono-allelic mutation analysis for identifying germline mutations
US5773695A (en) 1996-01-26 1998-06-30 North Carolina State University Plant nuclear scaffold attachment region and method for increasing gene expression in transgenic cells
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2288351A1 (en) 1997-05-01 1998-11-05 Amgen Inc. Chimeric opg polypeptides
US6214545B1 (en) 1997-05-05 2001-04-10 Third Wave Technologies, Inc Polymorphism analysis by nucleic acid structure probing
DE69834671T2 (en) 1997-08-05 2007-05-10 Stressgen Biotechnologies Corp., Victoria Immune response against HPV antigens produced by compositions containing an HPV antigen and a stress protein or an expression vector capable of expressing these proteins
US6319691B1 (en) 1999-06-15 2001-11-20 Usa Universe Bioengineering, Inc. Fusion proteins comprising IFN-alpha2b and TM-alpha1
US6342362B1 (en) 1999-08-05 2002-01-29 Daniel S. Mytelka Methods and compositions for the purification of proteins or other macromolecules
KR101150584B1 (en) * 2002-11-15 2012-06-27 사노피 파스테르 바이오로직스 씨오 West nile virus vaccine
CN101123871B (en) 2003-05-05 2011-05-18 美国陶氏益农公司 Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
US20080034455A1 (en) * 2004-05-21 2008-02-07 Simon Fraser University Production Of A Protein Localized To The Endoplasmic Reticulum Protein Bodies In A Transgenic Plant And Seed

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112694A2 (en) * 2003-05-23 2004-12-29 Chiron Corporation Immunogenic reagents from west nile virus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHANG G-J J ET AL: "RECENT ADVANCEMENT IN FLAVIVIRUS VACCINE DEVELOPMENT", EXPERT REVIEW OF VACCINES, FUTURE DRUGS, LONDON, GB, vol. 3, no. 2, 1 January 2004 (2004-01-01), pages 199 - 220, XP009061787, ISSN: 1476-0584 *
PLOTKIN STANLEY A: "Vaccines, vaccination, and vaccinology.", JOURNAL OF INFECTIOUS DISEASES, vol. 187, no. 9, 1 May 2003 (2003-05-01), pages 1349 - 1359, XP009070448, ISSN: 0022-1899 *
SCHILLBERG S ET AL: "Opportunities for recombinant antigen and antibody expression in transgenic plants-technology assessment", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 23, no. 15, 7 March 2005 (2005-03-07), pages 1764 - 1769, XP004768051, ISSN: 0264-410X *
STREATFIELD S J: "Plant-based vaccines for animal health", REVUE SCIENTIFIQUE ET TECHNIQUE OFFICE INTERNATIONAL DES EPIZOOTIES, vol. 24, no. 1, April 2005 (2005-04-01), pages 189 - 199, XP009110074, ISSN: 0253-1933 *
WARZECHA H ET AL: "Oral Immunogenicity of Human Papillomavirus-Like Particles Expressed in Potato", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 77, no. 16, 1 August 2003 (2003-08-01), pages 8702 - 8711, XP002993767, ISSN: 0022-538X *

Also Published As

Publication number Publication date
AU2007353773A1 (en) 2008-11-27
US20090069229A1 (en) 2009-03-12
JP2010514698A (en) 2010-05-06
WO2008143713A2 (en) 2008-11-27
EP2099916A2 (en) 2009-09-16
BRPI0721141A2 (en) 2014-04-01
CA2671934A1 (en) 2008-11-27
AR064500A1 (en) 2009-04-08
US7888069B2 (en) 2011-02-15

Similar Documents

Publication Publication Date Title
IL250946A0 (en) Improved nanobodiestm against tumor necrosis factor-alpha
BR112012008790A2 (en) polynucleotide sequences, vector, fusion protein, method of producing a fusion protein, host cell, immunogenic composition, method of stimulating or inducing immune reaction, and uses of a polynucleotide sequence, of a vector, of a fusion protein or an immunogenic composition
WO2011008974A3 (en) Rsv f protein compositions and methods for making same
WO2010093627A3 (en) Fibronectin type iii domain based scaffold compositions, methods and uses
MX2009001778A (en) Immunogenic pcpa polypeptides and uses thereof.
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2008077945A3 (en) Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
WO2010057159A3 (en) Antigens that elicit immune response against flavivirus and methods of using same
WO2009001867A1 (en) Vaccine antigen capable of inducing cross-reacting and neutralizing antibody against high-risk-type human papillomavirus
WO2012047679A8 (en) Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria
WO2008137881A3 (en) Ehrlichia ewingii proteins, nucleic acids, and methods of their use
MX2012001495A (en) Porphyromonas gingivalis polypeptides.
WO2008143713A3 (en) Plant-made west nile virus (wnv) vaccines, vectors and plant codon optimized sequences
WO2016168214A3 (en) Immunogenic fusion proteins for the treatment of cancer
WO2006138435A3 (en) Methods for enhancing immune responses
WO2012045063A3 (en) Flavivirus domain iii vaccine
WO2012038832A3 (en) Generation of replicating chimeric measles virus - retrovirus particles
WO2007120603A3 (en) Immunogenic bcr-abl peptides and methods of use thereof
WO2008127450A3 (en) Linear expression cassette vaccines
WO2005082930A3 (en) An immunoreactive 38-kda ferric binding protein of ehrlichia canis and uses thereof
WO2008080112A3 (en) New fusion molecule based on novel taa variant
WO2008126065A3 (en) Polynucleotides and polypeptides involved in gestational malaria, and biological applications
WO2011128892A3 (en) Modified forms of pneumococcal surface immunogenic protein b (psipb)
WO2010077473A8 (en) Monoclonal antibodies that react with the capsule of bacillus anthracis
WO2007038083A3 (en) Heat shock proteins from mycobacterium leprae and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07874382

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007353773

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2671934

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009543249

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007353773

Country of ref document: AU

Date of ref document: 20071221

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007874382

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0721141

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090622